GLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
DOI:
https://doi.org/10.12775/QS.2026.77.76169Keywords
glucagon-like peptide 1, semaglutide, #cardiovascular risk, nephroprotection, chronic kidney disease, Neurological disorders, Obesity,, diabetes mellitus type 2, socioeconomic statusAbstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are primarily used in type 2 diabetes and obesity. Evidence suggests additional cardiovascular, renal, and neurological effects, with important socioeconomic implications.
Aim: To evaluate GLP-1 RA effects beyond metabolic control, focusing on cardiovascular, renal, neurological, physical activity, and socioeconomic outcomes.
Material and methods: PubMed, Embase, and Scopus were searched for studies published from 2022 to 2026. Adult human studies assessing cardiovascular, renal, cerebrovascular, neurological or socioeconomic outcomes were included. After screening, 39 publications were qualitatively synthesized.
Results: GLP-1 RAs were associated with reduced major adverse cardiovascular events, cardiovascular mortality, myocardial infarction, and selected heart-failure outcomes. Semaglutide reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease. Neurological effects included reduced cerebrovascular events and intracranial pressure, while evidence regarding cognition and neurodegenerative disorders remained heterogeneous.
Conclusions: GLP-1 RAs exert multisystem effects beyond metabolic control, including cardiovascular and renal protection and neurological effects. Their expanding use may provide substantial health benefits but also raises concerns regarding treatment costs and socioeconomic disparities in access.
References
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., Ripa, M. S., Hovingh, G. K., Brown-Frandsen, K., Bain, S. C., Cavender, M. A., Gislum, M., David, J.-P., & Buse, J. B. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. The New England Journal of Medicine, 392(20), 2001–2012. https://doi.org/10.1056/NEJMoa2501006
Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Hadjadj, S., ... & Pratley, R. E. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. The New England Journal of Medicine, 391(2), 109–121. https://doi.org/10.1056/NEJMoa2403347
Lin, H.-T., Tsai, Y.-F., Liao, P.-L., & Wei, J. C.-C. (2025). Neurodegeneration and after semaglutide and tirzepatide in patients with diabetes and obesity. JAMA Network Open, 8(7), Article e2521016. https://doi.org/10.1001/jamanetworkopen.2025.21016
Fang, S., Cui, F., & Drucker, D. J. (2025). Glucagon-like peptide-1 medicines in neurological and psychiatric disorders. Cell Reports Medicine, 6(12), Article 102511. https://doi.org/10.1016/j.xcrm.2025.102511
Gonzalez-Rellan, J. M., & Drucker, D. J. (2025). Expanding dimensions of GLP-1 biology and therapy. Cell Reports Medicine, 6(8), 102214. https://doi.org/10.1016/j.xcrm.2025.102214
Hwang, J.H., Laiteerapong N., Huang E.S., Mozaffarian D., Fendrick A., Kim D.D. (2025) ‘Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity’, JAMA Health Forum, 6(4). https://doi.org/10.1001/jamahealthforum.2025.0905
Shi, Q., Nong, K., Vandvik, P. O., Guyatt, G. H., Schnell, O., Rydén, L., Marx, N., Brosius, F. C., 3rd, Mustafa, R. A., Agarwal, A., Zou, X., Mao, Y., Asadollahifar, A., Chowdhury, S. R., Zhai, C., Gupta, S., Gao, Y., Lima, J. P., Numata, K., Qiao, Z., … Li, S. (2023). Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical research ed.), 381, e074068. https://doi.org/10.1136/bmj-2022-074068
McGowan, B., Ciudin, A., Baker, J. L., Busetto, L., Dicker, D., Frühbeck, G., Goossens, G. H., Monami, M., Sbraccia, P., Martinez-Tellez, B., Woodward, E., & Yumuk, V. (2025). A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nature medicine, 31(10), 3317–3329. https://doi.org/10.1038/s41591-025-03978-z
Sadraei, S., Aarabi, A., Rajai Firouzabadi, S., Alinejadfard, M., Mohammadi, I., & Jolfayi, A. G. (2025). Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials. BMC cardiovascular disorders, 25(1), 881. https://doi.org/10.1186/s12872-025-05278-3
Tang, A. S. P., Hsu, J. T. Y., Chong, S. K. S., Quek, J., Shek, G., Sulaimi, F., Chan, K. E., Anand, V. V., Chong, B., Mehta, A., Toh, S. A., Muthiah, M., Dimitriadis, G. K., le Roux, C. W., Chan, M. Y., Mamas, M. A., Chin, Y. H., & Chew, N. W. S. (2025). Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovascular diabetology, 24(1), 285. https://doi.org/10.1186/s12933-025-02840-3
Deanfield, J., Verma, S., Scirica, B. M., Kahn, S. E., Emerson, S. S., Ryan, D., Lingvay, I., Colhoun, H. M., Plutzky, J., Kosiborod, M. N., Hovingh, G. K., Hardt-Lindberg, S., Frenkel, O., Weeke, P. E., Rasmussen, S., Goudev, A., Lang, C. C., Urina-Triana, M., Pietilä, M., Lincoff, A. M., … SELECT Trial Investigators (2024). Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet (London, England), 404(10454), 773–786. https://doi.org/10.1016/S0140-6736(24)01498-3
Krychtiuk, K. A., Marquis-Gravel, G., Murphy, S., Alexander, K. P., Chiswell, K., Green, J. B., Leiter, L. A., Lopes, R. D., Del Prato, S., Jones, W. S., McMurray, J. J. V., Hernandez, A. F., & Granger, C. B. (2024). Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. European heart journal. Cardiovascular pharmacotherapy, 10(4), 279–288. https://doi.org/10.1093/ehjcvp/pvae006
Pratley, R. E., Tuttle, K. R., Rossing, P., Rasmussen, S., Perkovic, V., Nielsen, O. W., Mann, J. F. E., MacIsaac, R. J., Kosiborod, M. N., Kamenov, Z., Idorn, T., Hansen, M. B., Hadjadj, S., Bakris, G., Baeres, F. M. M., Mahaffey, K. W., & FLOW Trial Committees and Investigators (2024). Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial. Journal of the American College of Cardiology, 84(17), 1615–1628. https://doi.org/10.1016/j.jacc.2024.08.004
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., Murakami, M., Packer, M., & SUMMIT Trial Study Group (2025). Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation, 151(10), 656–668. https://doi.org/10.1161/CIRCULATIONAHA.124.072679
Schou, M., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Patel, S., Chinnakondepalli, K. M., Harring, S., Abildstrøm, S. Z., Liisberg, K., Kosiborod, M. N., & STEP-HFpEF Trial Committees and Investigators (2024). Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program. Journal of the American College of Cardiology, 84(3), 247–257. https://doi.org/10.1016/j.jacc.2024.04.038
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., Idorn, T., Ji, L., Mahaffey, K. W., Perkovic, V., Rasmussen, S., Schmieder, R. E., Pratley, R. E., & Tuttle, K. R. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature medicine, 30(10), 2849–2856. https://doi.org/10.1038/s41591-024-03133-0
Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., Wilding, J. P. H., Mann, J. F. E., Tuttle, K. R., Idorn, T., Rathor, N., & Lincoff, A. M. (2024). Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature medicine, 30(7), 2058–2066. https://doi.org/10.1038/s41591-024-03015-5
Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., Wolthers, B., Zinman, B., & Perkovic, V. (2022). Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 145(8), 575–585. https://doi.org/10.1161/CIRCULATIONAHA.121.055459
Marzano, F., Paolillo, S., Gargiulo, P., Cotticelli, C., Di Santo, M., Nardi, E., Abbellito, G. M., Liccardi, L., Perrone Filardi, F., Bruzzese, D., & Perrone Filardi, P. (2026). Effects of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a systematic review and meta-analysis. Cardiovascular diabetology, 25(1), 234. https://doi.org/10.1186/s12933-026-03215-y
Apperloo, E. M., Cherney, D. Z. I., Kuhlman, A. B., Mann, J. F. E., Rasmussen, S., Rossing, P., Tuttle, K. R., Vrhnjak, B., & Heerspink, H. J. L. (2025). Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 40(2), 352–359. https://doi.org/10.1093/ndt/gfae150
Mitchell, J. L., Lyons, H. S., Walker, J. K., Yiangou, A., Grech, O., Alimajstorovic, Z., Greig, N. H., Li, Y., Tsermoulas, G., Brock, K., Mollan, S. P., & Sinclair, A. J. (2023). The effect of GLP-1RA exenatide on idiopathicintracranial hypertension: a randomized clinical trial. Brain, 146(5), 1821–1830. https://doi.org/10.1093/brain/awad003
Grech, O., Mitchell, J. L., Lyons, H. S., Yiangou, A., Thaller, M., Tsermoulas, G., Brock, K., Mollan, S. P., & Sinclair, A. J. (2024). Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressurelowering agent, on cognition in idiopathic intracranial hypertension. Eye, 38(7), 1374–1379. https://doi.org/10.1038/s41433-023-02908-y
Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023). GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: A systematic review and meta-analysis of randomized controlledtrials. The Journal of Clinical Endocrinology & Metabolism, 108(7), 1806–1812. https://doi.org/10.1210/clinem/dgad076
Zhu, H., Yang, B., Lu, L., Li, Y., Sui, R., Liu, K., Tan, S., Wang, L., Qiu, J., Zhong, J., Wei, T., Bei, Y., Huang, J., Zhang, S., Ji, Y., Wu, W., Li, Y., Huang, Y., Chen, Y., Huang, X., Zeng, G., Zhang, Y., Huang, L., Li, H., Wang, X., Wang, Y., & Xu, A. (2026). Liraglutide in acute minor ischemic stroke or high-risk transient ischemic attack with type 2 diabetes: The LAMP randomized clinical trial. JAMA Internal Medicine, 186(1), 46–54. https://doi.org/10.1001/jamainternmed.2025.5684
Lu, L., Yang, B., Wang, Y., Zhu, C., Liu, Z., Li, F., Yang, S., Liu, Y., Yang, Y., Liu, X., Huang, L., Xu, A., & Zhu, H. (2026). Liraglutide and recurrent stroke by baseline insulin resistance: A post hoc analysis of the LAMP trial. Stroke. https://doi.org/10.1161/STROKEAHA.125.056010
Edison, P., Femminella, G. D., Ritchie, C., Nowell, J., Holmes, C., Walker, Z., Ridha, B., Raza, S., Livingston, N. R., Frangou, E., Love, S., Williams, G., Lawrence, R., Mcfarlane, B., Archer, H., Coulthard, E., Underwood, B. R., Koranteng, P., Karim, S., Bannister, C., Perneczky, R., Prasanna, A., Junaid, K., McGuinness, B., Nilforooshan, R., Macharouthu, A., Donaldson, A., Thacker, S., Russell, G., Malik, N., Mate, V., Knight, L., Kshemendran, S., Holscher, C., Mansouri, A., Chester-Jones, M., Holmes, J., Tan, T., Williams, S., Ashraf, A., Brooks, D. J., Harrison, J., Hinz, R., Tadros, G., Passmore, A. P., & Ballard, C. (2026). Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nature Medicine, 32(1), 353–361. https://doi.org/10.1038/s41591-025-04106-7
Koychev, I., Reid, G., Nguyen, M., Mentz, R. J., Joyce, D., Shah, S. H., & Holman, R. R. (2024). Inflammatory proteins associated with Alzheimer’s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial. Alzheimer’s Research & Therapy, 16(1), 212. https://doi.org/10.1186/s13195-024-01573-x
Wilson, J. M., Dage, J. L., Qian, H.-R., Irelan, C. L., Crowder, H. S., Duffin, K. L., Mintun, M., Brooks, D. A., Gerstein, H. C., & Bethel, M. A. (2026). Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis. Alzheimer’s & Dementia, 22(4), e71391. https://doi.org/10.1002/alz.71391
Corcoran, E., Kettlety, M., Mogul, U., Ndiforngwah Azah, J., & Cork, S. C. (2026). The effects of GLP-1 receptor agonists on Alzheimer's pathophysiology: A systematic review. Molecular and Cellular Neuroscience, 137, 104091. https://doi.org/10.1016/j.mcn.2026.104091
Elghanam, Y., & Kim, E. (2026). Evaluating the clinical effects of GLP-1 receptor agonists for Alzheimer's and Parkinson's diseases using minimal clinically important difference: systematic review and meta-analysis. Archivesof Pharmacal Research, 49(5), 691–712. https://doi.org/10.1007/s12272-026-01615-y
Vijiaratnam, N., Girges, C., Auld, G., McComish, R., King, A., Skene, S. S., Hibbert, S., Wong, A., Melander, S., Gibson, R., Matthews, H., Dickson, J., Carroll, C., Patrick, A., Inches, J., Silverdale, M., Blackledge, B., Whiston, J., Hu, M., Welch, J., Duncan, G., Power, K., Gallen, S., Kerr, J., Chaudhuri, K. R., Batzu, L., Rota, S., Jabbari, E., Morris, H., Limousin, P., Greig, N., Li, Y., Libri, V., Gandhi, S., Athauda, D., Chowdhury, K., & Foltynie, T. (2025). Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. The Lancet, 405(10479), 627–636. https://doi.org/10.1016/S0140-6736(24)02808-3
Ali, M., Sharma, A., Paruchuri, A., Shahzad, F., Khalid, M. B., Karthik, K. N. B., Avanaki, M., Nithyanandam, A., Khan, T., & Suresh, V. (2026). Efficacy of GLP-1 receptor agonists in Parkinson’s disease: a systematic reviewand exploratory network meta-analysis of randomized controlled trials. Neurological Sciences, 47(5), 432. https://doi.org/10.1007/s10072-026-08929-1
Mendonça, M. F., Interaminense, A. C., do R. Barros, G. S. T., Rabelo, L. A., de Oliveira, P. G., Sales, R. F., de C. Lyra, A. M. V., & de S. e Silva, H. R. (2026). Efficacy and safety of GLP-1 receptor agonists in Parkinson’sdisease: a systematic review and meta-analysis of randomized clinical trials. Neurological Sciences, 47(6), 484. https://doi.org/10.1007/s10072-026-09084-3
Evans, M., Evans, W., Godbeer, F., Edgar, L., Spaepen, E., & Davies, A. L. (2025). Analysis of tirzepatide acquisition costs and weight reduction outcomes in the United Kingdom: Insights from the SURMOUNT-1study. Advances in Therapy, 42(6), 2821–2832. https://doi.org/10.1007/s12325-025-03194-8
Hasselbalch, R. B., Andrea, M. K., Nolsøe, C. V., Hindborg, M., Yazdanfard, P. D. W., Sørensen, K. K., Blomberg, S. N. F., Christensen, H. C., Graff, C., Denholt, C. S., Afzal, S., Nordestgaard, B. G., Kragholm, K., Bundgaard, H., Iversen, K. K., Torp-Pedersen, C., & Andersen, M. P. (2025). Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark. The LancetRegional Health - Europe, 56, 101398. https://doi.org/10.1016/j.lanepe.2025.101398
Pandey, A., Ye, Y., Wells, C. R., Singer, B. H., & Galvani, A. P. (2024). Estimating the lives that could be saved by expanded access to weight-loss drugs. Proceedings of the National Academy of Sciences of the United States of America, 121(43), e2412872121. https://doi.org/10.1073/pnas.2412872121
Jensen, S. B. K., Janus, C., Lundgren, J. R., Juhl, C. R., Sandsdal, R. M., Olsen, L. M., Andresen, A., Borg, S. A., Jacobsen, I. C., Finlayson, G., Stallknecht, B. M., Holst, J. J., Madsbad, S., & Torekov, S. S. (2022). Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nature Communications, 13(1), 4770. https://doi.org/10.1038/s41467-022-32307-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Weronika Wrona, Anna Wojdas , Wiktoria Wdowiak , Małgorzata Dorożalska , Małgorzata Jurczyk , Aleksandra Glapa , Hanna Ludwisiak , Maja Cwalina, Julia Owsik , Weronika Ryś
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 129
Number of citations: 0
